Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
Benzinga.com4d
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...
Absci shares jump as analyst lauds 'practical' AI drug company
"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...
Morningstar18d
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...
Nasdaq18d
Absci, AMD announce collaboration, strategic investment
Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s ...
Nasdaq18d
Absci Corporation Announces Strategic Collaboration with AMD to Enhance AI Drug Discovery Capabilities
Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...